DOCSLIB.ORG

248, 254 Adaptor Proteins , 241-242 Adrenal

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
248, 254 Adaptor Proteins , 241-242 Adrenal INDEX Acetylcholine, 202 Alternative splicing (continued) Acetylcholine receptors, nicotinic , 108 in Cav2genes, 385, 387-396 Action potentials (APs), 248, 254 therapeutic considerations, 396 Adaptor proteins , 241-242 in Cav3genes, 396-397 Adrenal fasciculata cells, 2I5-2I6 considerations for drug development, 400 Adrenal glomerulosa cells, 2 I5 identifying and confirming splice isoforms of a-Adrenergic modulation, 201 Caygenes, 374, 376 z I3-Adrenergic receptors (I3-AR), 348 in L-type Ca + genes, 379-385 I3-Adrenergic stimulation, 199 confers oxygen sensing to Cavl.2 Adrenocorticotropic hormone (ACI1I), 200, channels , 382 215-216 modifies inactivation, 380 eo-Agatoxins. 105 modifies pharmacology of Cavl.2, w-Aga-IA , 105-106 380-381 w-Aga-I1A and o>-Aga-I1B, 106 nomenclature of splice variants, 377, 379 processing of pre-mRNA, 375- 377 w-Aga-IIIA, o>-Aga-I1ill, and o>-Aga-IIID, 106 splice isoforms of Ca and Ca subunits , o>-Aga-IVA, 100,110,I II, 128,389 vl3z v134 398-400 and depolarizing shifts in activation voltage, I I I-I 14 AM-336 : see o>-CTx-CVID inhibits inward current by altering Amiloride, 194 chann el gating, I I 1-112 AMPA receptors, 320-321 knockoff of, 113 Amygdala neurons, central, 288 Analgesia, 163-165; see Pain sensitivities of splice forms of Cav2.1 to, Anandamide, 194 387 Anesthetics, 193 splice-form specific affinity for Cav2.1, Angiotensin II (All ), 202 126-127 structure, 157, 159 ANP: see Atrial natriuretic peptide Antiepileptics, 191, 193,213 w-Aga-IV A binding site, 124-126 Antihypertensive agents, 190, 384 low-affinity, 124-126 Antipsychotics, 193-194 o>-Aga-IVB (ro-Agatoxin-TK) , 159 Anxiety , increased Agelena opulenta, 146 in Cav2.3 knockout mice, 289 Agelenopsis aperta , 105, 106, 145, 146, 189 AP repolarization (afterhyperpolarization), Aldosterone, 215 254-255 Alternative splicing, 370 Arachidon ic acid (AA), 204 in Caval genes, 371-372 Assassin bug (Peirates turpis), 148, 159 C-terminal domain, 373 Ataxia, 283-284, 306, 307, 311-314,317,319 extracellular domain IV 53-54 linker, 372 in Cav2.1 knockout mice, 282-283 how many splice variants can be co-Atracotcxins. 106 generated from a Caval gene, w-Atracotox in-Hv2a, 106, 158 373-374 Atrax sp. lllawarra, 106 intracellular domain 11-111 loop (L . ), II III Atrial natriur etic peptide (ANP/AN F), 203, 215 372-373 411 412 INDEX Atrial tachycardia-inducedelectrical remodeling, Calmodulin (CaM) (continued) 209-210 interactions with al C, 257 Auditory hair cells, 279-280 determinants of COl and CDF in alC, 257-258 Baclofen, 202 Calmodulin (CaM)-aICinteractions, 257-258 BAPTA,249 constitutive, 258-259 Barbiturates, 193 lobe-specific, 259-260 Benzothiazepinefunction, individual residues Calmodulin (CaM) tethering, non-contiguous critical for, 42 sequencesinvolvedin,259 Benzothiazepines, 28 Calmodulin kinase II (CaMKII), 247 Bicucullinemethobromide (BMB), 294 associates with L-type channel, 261 BK channels, 251-256 as frequency detector for CDF, 260-262 Black mamba (Dendroaspis polylepispolylepis), autophosphorylation,260 116, 148 Calmodulin kinase II (CaMKII)-aICinteractions Bradykinin,203 . CDF depends upon, 261-262 Brazilianarmed spider (Phoneutria nigriventer), Calmodulin kinase II (CaMKII) substrate, alC 145, 146 subunit as, 261 Calmodulin kinase N (CaMKN), 246-248 CacnaJa gene (see Ca,2.I channels), 282, 283, Calmodulin kinase kinase (CaMKK), 245-248 306,307,309,311,312 Carbachol,201 Cacnalb gene (see Ca,2.2 channels), 284-287 Cardiac functions, 295 Cacna2d,318 Ca,I.2 channel and, 278, 384 CacnaJe gene (see Ca,2.3channels), 287-293 Cardiac hypertrophy, 207-209 CacnaIfgene (seeCa,I.4 channels), 308, 312 Cardiac muscle, 39, 195 2 Cacnb4,318-319 Ca + currents in Cacng2 ,319-321 distributionofT-type, 195, 197 CacnlaJ gene (see Ca,l.l channels), 304, 305 Cardiac myocytes, 278-279 Caenorhabditis elegans, mutations in, 322 Cardiac pacemaker activity, Ca,I.3 channel and, 280 CAG expansions, 306, 311 Cardiac pacemaking and abnormal electrical Calcicludine, 148 activity,210-212 binding site, 128 Cardiomyopathy, 207-209 effects on gating and permeation, 117 Cardiovasculardisease, treatment of, 79-80 Calcineurin, 247 CASK,241 -242 Calciseptine, dihydropyridine-like inhibitionby, Cav/34 gene structure, 398-400 116 Ca.I (L-type)channel inhibitors, 29 Calcium channel antagonists, L-type aliphatic, 30 actions, 25-27 nonselective, 30 cardiovascular profile, 23 weak,30 conbrcrlndications, 53-54 Ca.l (L-type)channel subtypes, pharmacologyof, differentialinteraction with L-type calcium 38-39 channel splice forms, 39 Cayl (L-type) channels, 27-28, 103-104, drug structures, 24 277-281;see also L-type channels interactionswith non-ion channel targets, 44 L-type activator and antagoniststructures, 35 interactionswith non-L-type channels, 46 L-type agonists, 32 perspectiveand future directions, 54-56 pharmacology pharmacokineticclassification,50 classes of drugs, 28-31 sites of action, 43-47 clinical action due to interaction at non­ that block non-L-type channels, 46 channel receptors,47 therapeuticuses, 23 localizationand definition receptor sites, vascularselectivity, 27 40-43 Calciumchannel blockers, classical, 190 peptide toxins, 32-33 Calciumchannels; see also specijictopics sites of drug action, 43-47 nomenclatureof voltage-operated, 187 structure-activity relationships, 33-38 Calcium-dependentfacilitation (CDF), 256-262 activation and inactivation relationshipsfor Calcium-dependentinactivation (COl), 256-261, Ca2+ currents, 184 381 Ca.I .I , 304-306; see also Calcium channel Calcium regulation,cellular, 22 antagonists Calmodulin (CaM) hypokalemicperiodic paralysis and mutations calcium channels and, 257-262 in, 304-306 calcium-dependentgating, 256-257 INDEX 413 Cav\.2,278-279 Cav2,3 knockout mice, R-type currents in,288-289 cardiacand smooth muscle spliceforms,39 Cav2.3 modulators, 83; see SNX-482 spliceisoforms, 379-382,384 Cav3 (T-type) channels, 104, 183,216--217, therapeutic considerations, 384 293-294 voltage dependent gatingkinetics, 12-13 in cardiovascular physiology and pathology, Cay 1.2channels; see alsoCalmodulin 210-212 N-terminal variants of, 384 chemical structuresof drugs blocking, 192, truncated formsof, 382 193 Cavl .2 gene,structureof human, 378 in endocrine system,214-216 Cav 1.3 in growthanddevelopment, 205-210 spliceisoforms of, 384 growthand differentiation, 205-207 sitesof splicing, 384-385 tissueremodeling and repair,207 therapeutic considerations, 385 in humancells, 195-196,200 uniquepharmacology, 38-39, 104 modulation, 199-204 Cav 1.3channels, 279-281 molecular pharmacology of Ca.J channels, Cavl .3 knockout miceare deaf,279-280 183,188-194 Cav\.3 gene, structure of human,383 inorganic ions, 189 Cav2 channel antagonists, 7J-80 in nervoussystemphysiology and pathology, Cav2 channels, 73-74, 281-293 212-214 2 Cav2 .1channelmodulators, 80-83 T-typeCa + currentsand associated channel Cav2.! channelopathies, 81-83 proteins Cav2.! channels (P- or P/Q-type channels), electrophysiological characterization, 160-163,282-284,399,400 184-186 mutations, 306--318 molecular characterization, 186--187 P/Qcurrentdensityand ataxicphenotype, tissuelocalization, 194-199 283-284 in vivo pharmacology and function, 204 P/Q-type channelis encoded solelyby, 283 Cav3.! channel, 293-294 and pain,80 Cav3 .1 knockout mice,burstmodefiringof action restingstateanduse-dependent blockof, 2, 3 potentials lackingin neuronsfrom, spliceisoforms of, 385, 387-391 293-294 Cvterminus, 390-391 Cellgrowth, proliferation, and differentiation, intracellular domainII-III loop(LU_III), 205-207 390 Cellularfunctions of calciumchannel subtypes, intracellular I-IIloop(LI-U), 387-388 237-238 ;see alsospecificcellular IVS3-IVS4 extracellular linker,389-390 functions toxin selectivity, 100-102, 126--128 Central amygdala (CeA)neurons,288 Cav2.1 gene,structureof, 386 Cerebellum, 282, 315, 317 Cav2.2 (N-type) channelantagonists, 165 Channel block, accounting for molecular Cav2.2 (N-type) channels, 101-103,284-287,351 mechanism of, 5, 7 oi-conotoxin affinityfor partiallyinactivated UIA channels: see Cav2.1 channels vs. noninactivated, 121 UIB channels: see Cav2.2 channels potencyand selectivity of co-conotoxins for, UIC channels: see Cay 1.2channels 101-103 UID channels: see Cay\.3 channels spliceisoforms of, 391 , 393-395 UIE channels: see Cav2.3 channels C-terminus, 395 UIF channels: see Cav\.4 channels IVS3-IVS4extracellular linker, 391 UIG channels: see Cav3.! channels longintracellular domain II-III loop UIH channels: see Cav3.2 channels (Lu-III), 393-394 Un channels: see Cav3,3 channels Cav2.2 exon31a UIS channels: Ca.l .I channels dominant expression in peripheral neurons, see Chlordiazepoxide, 193 393 Climbing fiber-Purkinje cell (CF-PC), 315-316 Cav2.2 gene,structureof human,392 2 Conductance ofT-type Ca + currents,185 Ca .2 knockout mice v2 Congenital stationary nightblindness (CSNB), abnormal emotional statein, 285 308,312 abnormal pain responses in, 285-287 Conotoxin GS, 151 alteredsympathetic functions in, 284-285 N-typecurrentis missingin, 284 rc-conotcxin inhibition effectsof non-pore domainson, 121-122 Cav2.3 (R-type) channels, 103, 188,287-293 spliceisoforms of, 395-396 effectson mutations at pore domainon, 118-120 414 INDEX o>-conotoxin-MVlIA: see o>-CTx-MVIIA Cysteine string protein (CSP), 352 (o>-conotoxin-MVlIA) to-conotoxlns, 107 Dendroaspis polylepis polylepis(black mamba), affinity for partially inactivated vs. 116,148 noninactivated Ca.2.2 N-type IA-Dihydropyridine binding channels, 121 correlates with potency, 53 flexibility , folding and stability, IS1-153
Load more

Recommended publications
  • Family, Is a Potent Blocker of High-Threshold Ca2+ Channels with A
    Proc. Nat!. Acad. Sci. USA Vol. 91, pp. 878-882, February 1994 Cell Biology Calcicludine, a venom peptide of the Kunitz-type protease inhibitor family, is a potent blocker of high-threshold Ca2+ channels with a high affinity for L-type channels in cerebellar granule neurons (tolns/AIZheImer dsase/n inhibitor) HUGUES SCHWEITZ, CATHERINE HEURTEAUX, PATRICK BoIs*, DANIELLE MOINIER, GEORGES ROMEY, AND MICHEL LAZDUNSKIt Institut de Pharmacologie Mol6culaire et Cellulaire, 660 Route des Lucioles, Sophia Antipolis, 06560 Valbonne, France Communicated by JosefFried, October 8, 1993 ABSTRACT Calcicludine (CaC) is a 60-amino acid poly- acid and chromatographed onto a Sephadex G50 column. The peptide from the venom of Dendroaspis angusticeps. It Is peptidic fraction was directly loaded onto a TSK (Toyosoda, structually homologous to the Kunitz-type protease Inhibitor, Japan) SP 5PW (21.5 x 150 mm) column equilibrated with 1% to dendrotoxins, which block K+ c , and to the protease acetic acid. Peptide fractions were then eluted (Fig. 1 Top), inhibItor domain of the amyloid P protein that accumultes in with a linear gradient from 1% acetic acid to 1 M ammonium Alzbeimer disease. Voltage-lamp experiments on a variety of acetate at a flow rate of 8 ml/min. The fractions obtained excitable cells have shown that CaC specificaly blocks most of the hih-threshold Ca2+ che (L-, N-, or P-type) in the (horizontal bars) were designated A-R. Fraction Q was 10-100 nM range. Particularly high densities of specific 125I- lyophilized, redissolved in 1 ml of 0.5% trifluoroacetic acid abeled CaC binding sites were found in the olfactory bulb, in plus 0.9%6 triethylamine in water, and loaded on a Lichrosorb the molecular layer ofthe dentate gyrus and the stratum oriens RP18 7-ikm (250 x 10 mm) column (Merck, Darmstadt, ofCA3 field in the hippocanal formation, and in the granular Germany) and eluted (Fig.
    [Show full text]
  • In the Molecular Evolution of Snake Venom Proteins Robin Doley National University of Singapore
    University of Northern Colorado Scholarship & Creative Works @ Digital UNC School of Biological Sciences Faculty Publications School of Biological Sciences 2009 Role of Accelerated Segment Switch in Exons to Alter Targeting (Asset) in the Molecular Evolution of Snake Venom Proteins Robin Doley National University of Singapore Stephen P. Mackessy University of Northern Colorado R. Manjunatha Kini National University of Singapore Follow this and additional works at: http://digscholarship.unco.edu/biofacpub Part of the Biology Commons Recommended Citation Doley, Robin; Mackessy, Stephen P.; and Kini, R. Manjunatha, "Role of Accelerated Segment Switch in Exons to Alter Targeting (Asset) in the Molecular Evolution of Snake Venom Proteins" (2009). School of Biological Sciences Faculty Publications. 7. http://digscholarship.unco.edu/biofacpub/7 This Article is brought to you for free and open access by the School of Biological Sciences at Scholarship & Creative Works @ Digital UNC. It has been accepted for inclusion in School of Biological Sciences Faculty Publications by an authorized administrator of Scholarship & Creative Works @ Digital UNC. For more information, please contact [email protected]. BMC Evolutionary Biology BioMed Central Research article Open Access Role of accelerated segment switch in exons to alter targeting (ASSET) in the molecular evolution of snake venom proteins Robin Doley1, Stephen P Mackessy2 and R Manjunatha Kini*1 Address: 1Protein Science Laboratory, Department of Biological Sciences, National University of
    [Show full text]
  • Composition Modulating Botulinum Neurotoxin Effect
    (19) *EP003753568A1* (11) EP 3 753 568 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 23.12.2020 Bulletin 2020/52 A61K 38/17 (2006.01) A61K 31/205 (2006.01) A61K 31/4178 (2006.01) A61K 38/48 (2006.01) (2006.01) (2006.01) (21) Application number: 19181635.4 A61P 9/00 A61P 21/00 A61P 29/00 (2006.01) (22) Date of filing: 21.06.2019 (84) Designated Contracting States: •Cros, Cécile AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 74580 Viry (FR) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Hulo, Nicolas PL PT RO RS SE SI SK SM TR 1252 Meinier (CH) Designated Extension States: • Machicoane, Mickaël BA ME 1290 Versoix (CH) Designated Validation States: KH MA MD TN (74) Representative: Barbot, Willy Simodoro-ip (71) Applicant: Fastox Pharma SA 82, rue Sylvabelle 1003 Lausanne (CH) 13006 Marseille (FR) (72) Inventors: • Le Doussal, Jean-Marc 1007 Lausanne (CH) (54) COMPOSITION MODULATING BOTULINUM NEUROTOXIN EFFECT (57) The present invention relates to a method for cholinergic neuronal transmission to the botulinum neu- modulating the effect of a botulinum neurotoxin compo- rotoxin composition. The invention also relates to com- sition, that is accelerating the onset of action and /or ex- positions comprising at least one postsynaptic inhibitor tending the duration of action and/or enhancing the in- of cholinergic neuronal transmission and a botulinum tensity of action of a botulinum neurotoxin composition, neurotoxin, and their uses for treating aesthetic or ther- comprising adding at least one postsynaptic inhibitor of apeutic conditions.
    [Show full text]
  • Review Article Metal Toxicity at the Synapse: Presynaptic, Postsynaptic, and Long-Term Effects
    Hindawi Publishing Corporation Journal of Toxicology Volume 2012, Article ID 132671, 42 pages doi:10.1155/2012/132671 Review Article Metal Toxicity at the Synapse: Presynaptic, Postsynaptic, and Long-Term Effects Sanah Sadiq, Zena Ghazala, Arnab Chowdhury, and Dietrich Busselberg¨ Weill Cornell Medical College in Qatar, Qatar Foundation—Education City, P.O. Box 24144, Doha, Qatar Correspondence should be addressed to Dietrich Busselberg,¨ [email protected] Received 9 May 2011; Accepted 5 July 2011 Academic Editor: David O. Carpenter Copyright © 2012 Sanah Sadiq et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Metal neurotoxicity is a global health concern. This paper summarizes the evidence for metal interactions with synaptic transmission and synaptic plasticity. Presynaptically metal ions modulate neurotransmitter release through their interaction with synaptic vesicles, ion channels, and the metabolism of neurotransmitters (NT). Many metals (e.g., Pb2+, Cd2+,andHg+)also interact with intracellular signaling pathways. Postsynaptically, processes associated with the binding of NT to their receptors, activation of channels, and degradation of NT are altered by metals. Zn2+, Pb2+, Cu2+, Cd2+, Ni2+, Co2+, Li3+, Hg+,and 3+ 2+ 2+ methylmercury modulate NMDA, AMPA/kainate, and/or GABA receptors activity. Al , Pb , Cd ,andAs2O3 also impair synaptic plasticity by targeting molecules such as CaM, PKC, and NOS as well as the transcription machinery involved in the maintenance of synaptic plasticity. The multiple effects of metals might occur simultaneously and are based on the specific metal species, metal concentrations, and the types of neurons involved.
    [Show full text]
  • Isolation and Characterization of Snake Venom Proteins and Peptides from Members of Viperidae and Elapidae Snake Families from Kilifi County
    ISOLATION AND CHARACTERIZATION OF SNAKE VENOM PROTEINS AND PEPTIDES FROM MEMBERS OF VIPERIDAE AND ELAPIDAE SNAKE FAMILIES FROM KILIFI COUNTY OTIENO KEPHER ONYANGO MASTER OF SCIENCE (Molecular Medicine) JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY 2018 Isolation and Characterization of Snake Venom Proteins and Peptides from Members of Viperidae and Elapidae Snake Families from Kilifi County Otieno Kepher Onyango A thesis submitted in partial fulfillment for the Degree of Master of Science in Molecular Medicine in the Jomo Kenyatta University of Agriculture and Technology 2018 DECLARATION This thesis is my original work and has not been presented for a degree in any other University. Signature: ……………………… Date: ……………………….. Otieno Kepher Onyango This thesis has been submitted for examination with our approval as University supervisors. Signature: ……………………..... Date: …………………………. Prof. Joseph Kangangi Gikunju, PhD JKUAT, Kenya Signature: ……………………….... Date: ………………………… Dr. Kimani Gachuhi, PhD KEMRI, Kenya. ii DEDICATION This work is dedicated to my parents, Mr.Gabriel Otieno and Mrs. Christine Otieno, my wife Mrs. Florence Onyango and our two daughters M/s. Michelle and M/s. Maureen for making sure that I had easy moment during my studies. I wish you many blessings from God Almighty. iii ACKNOWLEDGEMENT Completing a major research project in snake venom proteomics would not have been made possible without the moral and material support from several individuals who deserve so much appreciation more than just a piece of an acknowledgement. First to my hardworking university and research supervisors: Prof. Joseph K.Gikunju and Dr. Kimani Gachuhi, I want to thank you so much for providing me with the required academic and research advice for the successful completion of my research work and their assistance with securing laboratory space within the required time.
    [Show full text]
  • 9-Tetrahydrocannabinol and Cannabinol Activate Capsaicin-Sensitive Sensory Nerves Via a CB1 and CB2 Cannabinoid Receptor-Independent Mechanism
    The Journal of Neuroscience, June 1, 2002, 22(11):4720–4727 ⌬9-Tetrahydrocannabinol and Cannabinol Activate Capsaicin-Sensitive Sensory Nerves via a CB1 and CB2 Cannabinoid Receptor-Independent Mechanism Peter M. Zygmunt, David A. Andersson, and Edward D. Ho¨ gesta¨tt Department of Clinical Pharmacology, Institute of Laboratory Medicine, Lund University Hospital, SE-221 85 Lund, Sweden Although ⌬9-tetrahydrocannabinol (THC) produces analgesia, nerves is intact in vanilloid receptor subtype 1 gene knock-out its effects on nociceptive primary afferents are unknown. These mice. The THC response depends on extracellular calcium but neurons participate not only in pain signaling but also in the does not involve known voltage-operated calcium channels, local response to tissue injury. Here, we show that THC and glutamate receptors, or protein kinases A and C. These results cannabinol induce a CB1/CB2 cannabinoid receptor- may indicate the presence of a novel cannabinoid receptor/ion independent release of calcitonin gene-related peptide from channel in the pain pathway. capsaicin-sensitive perivascular sensory nerves. Other psych- otropic cannabinoids cannot mimic this action. The vanilloid Key words: calcitonin gene-related peptide; cannabinoids; receptor antagonist ruthenium red abolishes the responses to cannabinol; cannabis; capsaicin; nociceptors; pain; receptors, THC and cannabinol. However, the effect of THC on sensory sensory; tetrahydrocannabinol Marijuana contains a mixture of different cannabinoids, of which (CGRP) and substance P, in both the periphery and the spinal ⌬ 9-tetrahydrocannabinol (THC), the major psychoactive ingredi- cord (Holzer, 1992; Szallasi and Blumberg, 1999). In the vascu- ent, has been characterized extensively with regard to analgesic lature, this leads to vasodilatation and increased vascular perme- and anti-inflammatory effects (Mechoulam and Hanus, 2000; ability (Holzer, 1992).
    [Show full text]
  • Containing (ECL) Cells by Stimulating Influx of Ca2+ Through Different Ca2+ Channels
    Gastrin and the neuropeptide PACAP evoke secretion from rat stomach histamine- containing (ECL) cells by stimulating influx of Ca2+ through different Ca2+ channels Lindström, Erik; Eliasson, Lena; Björkqvist, Maria; Håkanson, Rolf Published in: Journal of Physiology 2001 Link to publication Citation for published version (APA): Lindström, E., Eliasson, L., Björkqvist, M., & Håkanson, R. (2001). Gastrin and the neuropeptide PACAP evoke secretion from rat stomach histamine-containing (ECL) cells by stimulating influx of Ca2+ through different Ca2+ channels. Journal of Physiology, 535(3), 663-677. http://jp.physoc.org/cgi/content/abstract/535/3/663 Total number of authors: 4 General rights Unless other specific re-use rights are stated the following general rights apply: Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Read more about Creative commons licenses: https://creativecommons.org/licenses/ Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. LUND UNIVERSITY PO Box 117 221 00 Lund +46 46-222 00 00 Download date: 27.
    [Show full text]
  • Cannabinoids Enhance NMDA-Elicited Ca2+ Signals In
    The Journal of Neuroscience, October 15, 1999, 19(20):8765–8777 Cannabinoids Enhance NMDA-Elicited Ca21 Signals in Cerebellar Granule Neurons in Culture Jeffrey G. Netzeband, Shannon M. Conroy, Kathy L. Parsons, and Donna L. Gruol Department of Neuropharmacology, The Scripps Research Institute, La Jolla, California 92037 A physiological role for cannabinoids in the CNS is indicated by tered the membrane response to NMDA or passive membrane the presence of endogenous cannabinoids and cannabinoid properties of granule neurons, suggesting that NMDARs are not receptors. However, the cellular mechanisms of cannabinoid the primary sites of cannabinoid action. Additional Ca 21 imag- actions in the CNS have yet to be fully defined. In the current ing studies showed that cannabinoid enhancement of the Ca 21 study, we identified a novel action of cannabinoids to enhance signal to NMDA did not involve N-, P-, or L-type Ca 21 channels intracellular Ca 21 responses in CNS neurons. Acute application but was dependent on Ca 21 release from intracellular stores. of the cannabinoid receptor agonists R(1)-methanandamide, Moreover, the phospholipase C inhibitor U-73122 and the ino- 1 R( )-WIN, and HU-210 (1–50 nM) dose-dependently enhanced sitol 1,4,5-trisphosphate (IP3 ) receptor antagonist xestospon- the peak amplitude of the Ca 21 response elicited by stimulation gin C blocked the cannabinoid effect, suggesting that the can- of the NMDA subtype of glutamate receptors (NMDARs) in nabinoid enhancement of NMDA-evoked Ca 21 signals results 21 cerebellar granule neurons. The cannabinoid effect was from enhanced release from IP3-sensitive Ca stores.
    [Show full text]
  • Toxins Review Oglsigfsiaino Uastwrsvnmu Nml [5]
    toxins Review Spider Venom: Components, Modes of Action, and Novel Strategies in Transcriptomic and Proteomic Analyses Nicolas Langenegger *, Wolfgang Nentwig and Lucia Kuhn-Nentwig * Institute of Ecology and Evolution, University of Bern, Baltzerstrasse 6, CH-3012 Bern, Switzerland; [email protected] * Correspondence: [email protected] (N.L.); [email protected] (L.K.-N.) Received: 26 September 2019; Accepted: 18 October 2019; Published: 22 October 2019 Abstract: This review gives an overview on the development of research on spider venoms with a focus on structure and function of venom components and techniques of analysis. Major venom component groups are small molecular mass compounds, antimicrobial (also called cytolytic, or cationic) peptides (only in some spider families), cysteine-rich (neurotoxic) peptides, and enzymes and proteins. Cysteine-rich peptides are reviewed with respect to various structural motifs, their targets (ion channels, membrane receptors), nomenclature, and molecular binding. We further describe the latest findings concerning the maturation of antimicrobial, and cysteine-rich peptides that are in most known cases expressed as propeptide-containing precursors. Today, venom research, increasingly employs transcriptomic and mass spectrometric techniques. Pros and cons of venom gland transcriptome analysis with Sanger, 454, and Illumina sequencing are discussed and an overview on so far published transcriptome studies is given. In this respect, we also discuss the only recently
    [Show full text]
  • Item Name Catalog Number Quantity A-803467 A-105 10 Mg A
    Catalog Item Name Number Quantity A-803467 A-105 10 mg A-803467 A-105 25 mg A-803467 A-105 50 mg A-803467 A-105 100 mg Amlodipine A-110 250 mg Amlodipine A-110 1 g Amlodipine A-110 5 g Amlodipine A-110 10 g 4-Aminopyridine A-115 25 g 4-Aminopyridine A-115 100 g Amlodipine besylate A-120 10 mg Amlodipine besylate A-120 25 mg Amlodipine besylate A-120 50 mg Amlodipine besylate A-120 100 mg Amlodipine besylate A-120 500 mg Amlodipine besylate A-120 1 g Amlodipine besylate A-120 5 g Azelnidipine A-135 5 mg Azelnidipine A-135 10 mg Azelnidipine A-135 25 mg Azelnidipine A-135 50 mg Amiloride hydrochloride A-140 1 g Amiloride hydrochloride A-140 5 g Amiloride hydrochloride A-140 10 g Ambroxol hydrochloride A-145 1 g Ambroxol hydrochloride A-145 5 g Aconitine A-150 25 mg Aconitine A-150 50 mg Aconitine A-150 100 mg Aconitine A-150 250 mg Amitriptyline hydrochloride A-155 10 g Amitriptyline hydrochloride A-155 25 g Amitriptyline hydrochloride A-155 100 g Amentoflavone A-165 1 mg Amentoflavone A-165 5 mg Amentoflavone A-165 10 mg Amentoflavone A-165 25 mg AMG 9810 A-180 5 mg AMG 9810 A-180 10 mg AMG 9810 A-180 25 mg AMG 9810 A-180 50 mg AM 404 A-190 5 mg AM 404 A-190 10 mg AM 404 A-190 25 mg AM 404 A-190 50 mg A-889425 A-195 1 mg A-889425 A-195 5 mg A-889425 A-195 10 mg A-889425 A-195 25 mg A-889425 A-195 50 mg 3-AQC A-205 5 mg 3-AQC A-205 10 mg 3-AQC A-205 25 mg 3-AQC A-205 50 mg ANA-12 A-215 5 mg ANA-12 A-215 10 mg ANA-12 A-215 25 mg ANA-12 A-215 50 mg ANA-12 A-215 100 mg A 967079 A-225 5 mg A 967079 A-225 10 mg A 967079 A-225 25 mg A 967079
    [Show full text]
  • Block of Voltage-Gated Calcium Channels by Peptide Toxins Emmanuel Bourinet, Gerald Zamponi
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Archive Ouverte en Sciences de l'Information et de la Communication Block of voltage-gated calcium channels by peptide toxins Emmanuel Bourinet, Gerald Zamponi To cite this version: Emmanuel Bourinet, Gerald Zamponi. Block of voltage-gated calcium channels by peptide toxins. Neuropharmacology, Elsevier, 2016, 10.1016/j.neuropharm.2016.10.016. hal-02356298 HAL Id: hal-02356298 https://hal.archives-ouvertes.fr/hal-02356298 Submitted on 8 Nov 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Invited review Block of voltage-gated calcium channels by peptide toxins Emmanuel Bourinet, Gerald Zamponi To cite this version: Emmanuel Bourinet, Gerald Zamponi. Invited review Block of voltage-gated calcium channels by pep- tide toxins. Neuropharmacology, Elsevier, 2016, 10.1016/j.neuropharm.2016.10.016. hal-02356298 HAL Id: hal-02356298 https://hal.archives-ouvertes.fr/hal-02356298 Submitted on 8 Nov 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not.
    [Show full text]
  • 2014 Inhibitors Catalogue Low Res.Pdf
    1. Kinase Inhibitors 1. Kinase Inhibitors 1. Product Name Wako Cat. No. Pkg. Size Grade CAS No. Soluble in IC50 Storage Condition Summary A-83-01 【 TGF-β R I Kinase Inhibitor IV】 018-22521 2 mg for Cellbiology 909910-43-6 DMSO - Keep at -20℃. 014-22523 10 mg <Protein kinase inhibitor> Selective inhibitor of TGF-β type I receptor ALK5 kinase, type I activin/nodal receptor ALK4 and type I nodal receptor ALK7. Inhibits Smad2/3 phosphorylation and TGF-β-induced epithelial-to-mesenchymal transition. This product has little or no effect on bone morphogenetic protein type I receptors, p38 MAP kinases, and extracellular-regulated kinases. 17-AAG, 97.0+ % (HPLC) 012-20101 1 mg for Cellbiology 75747-14-7 DMSO, methanol EC50 of HSP90 = 7.2 μM Keep at -20℃. <Protein kinase inhibitor/ protein tyrosine kinase (PTK) inhibitor> Synthetic derivative of geldanamycin, which is one of the ansamycin antibiotics. 17-AAG inhibits the function of HSP90 by binding to the ATP binding site of HSP90. HSP90 inhibitors dephosphorylate Akt resulting in inactivation of Akt and apoptosis. AG 490, 95+% (TLC) IC of Dephosphorylation of EGF DMSO, DMF, 50 013-17181 5 mg for Biochemistry 134036-52-5 receptor tyrosine kinase: 1.2 μmol; Keep at -20℃. methanol EGF dependent cell proliferation: 6 μmol <PTK inhibitor> Specific and potent JAK-2 protein tyrosine kinase inhibitor. Also inhibits EGF receptor autophosphorylation. AG 1296 016-20121 5 mg for Cellbiology 146535-11-7 DMSO - Keep at -20℃. <PTK inhibitor> It inhibits signaling in human PDGF (platelet-derived growth factor) α receptor, PDGF β receptor, stem cell stimulating factor c-kit and FGF (fibroblast growth factor) receptor.
    [Show full text]